Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 41.4 EUR Market Closed
Market Cap: 1.6B EUR
Have any thoughts about
Biotest AG?
Write Note

Biotest AG
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotest AG
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Biotest AG
XETRA:BIO
Total Assets
€1.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
4%
BioNTech SE
NASDAQ:BNTX
Total Assets
€23B
CAGR 3-Years
115%
CAGR 5-Years
104%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Assets
€1.8B
CAGR 3-Years
4%
CAGR 5-Years
27%
CAGR 10-Years
15%
CureVac NV
NASDAQ:CVAC
Total Assets
€788.2m
CAGR 3-Years
-20%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Total Assets
€510m
CAGR 3-Years
26%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Total Assets
€890.4m
CAGR 3-Years
123%
CAGR 5-Years
86%
CAGR 10-Years
N/A
No Stocks Found

Biotest AG
Glance View

Market Cap
1.6B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO Intrinsic Value
32.12 EUR
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Biotest AG's Total Assets?
Total Assets
1.3B EUR

Based on the financial report for Sep 30, 2024, Biotest AG's Total Assets amounts to 1.3B EUR.

What is Biotest AG's Total Assets growth rate?
Total Assets CAGR 10Y
4%

Over the last year, the Total Assets growth was 0%. The average annual Total Assets growth rates for Biotest AG have been 6% over the past three years , 4% over the past five years , and 4% over the past ten years .

Back to Top